Vision, Skin Concerns Led Lyrica Reviewers To Consult Top FDA Staff, EMEA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Top CDER officials moderated the primary reviewers' instincts to delay approval of Pfizer's Lyrica until more data on dermatologic and visual effects better characterized the drug's risks, review documents show
You may also be interested in...
Pfizer Challenge To Lyrica Abuse Liability Assessment Delayed Approval
Pfizer removed the final hurdle to approval of Lyrica (pregabalin) when it relented in its opposition to FDA's assessment of the potential for abuse of the drug, agency review documents show
Pfizer Lyrica Review Notable For Complexity: Four NDAs, Three FDA Divisions
Pfizer’s Lyrica (pregabalin) application may be one of the most exhaustively reviewed NDAs of the user fee era, Lyrica’s complex regulatory history suggests.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011